Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of Exelon capsule and patch in Parkinson's disease dementia
2007-000350-31Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rivastigmine in Parkinson's disease dementia (PDD) (2 arms), sponsored by Novartis. Primary endpoints: Worsening of underlying motor symptoms of Parkinson's disease, Long-term safety of Exelon capsule and 1 more. Started Oct 2007; status: completed.
02
Drugs
rivastigmine
03
Conditions
Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on 2007-000350-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000350-31.